



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

December 09, 2024

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

**Subject: Submission of Outcome of the Board Meeting held on Wednesday, November 13, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 in Machine Readable Format**

**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to the above captioned subject, we hereby again submit the un-audited Financial Results for the quarter and half year ended September 30, 2024 which were approved in the Board Meeting held on Wednesday, November 13, 2024 in machine readable format.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Jasjot Singh  
Managing Director  
DIN: 01937631



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

November 13, 2024

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

**Subject: Outcome of the Board Meeting held on Wednesday, November 13, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, November 13, 2024 at 02.30 p.m concluded at 03.30 p.m. Following transactions were considered and approved:

1. The un-audited Financial Results for the quarter and half year ended September 30, 2024.
2. Limited Review Report for the quarter and half year ended September 30, 2024.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

JASJOT SINGH  
Digitally signed  
by JASJOT SINGH  
Date: 2024.11.13  
15:32:40 +05'30'

Jasjot Singh  
Managing Director  
DIN: 01937631

**AJOONI BIOTECH LIMITED**

**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2024 (in Lakhs)**

PARTICULARS	QUARTER ENDED				Year Ended (Audited)
	30.09.2024	30.06.2024	30.09.2023	Period Ended (UnAudited)	
				30.09.2024	
<b>I Income</b>					
Revenue from operations	2,572.44	2,565.85	1,947.99	5,138.29	4,048.26
Other income	30.96	3.67	29.00	34.63	36.22
<b>Total income from operations</b>	<b>2,603.40</b>	<b>2,569.52</b>	<b>1,976.99</b>	<b>5,172.92</b>	<b>4,084.48</b>
<b>II Expenses</b>					
Cost of Material Consumed	2,247.25	2,248.65	1,743.89	4,495.90	3,646.60
Change In Inventories	9.41	(1.64)	15.90	7.77	(3.18)
Employee benefit expenses	70.31	57.28	51.08	127.59	104.71
Finance costs	5.90	15.02	19.19	20.92	32.57
Depreciation and amortization expenses	22.56	22.32	21.34	44.88	42.25
Payment to NSE					
Other expenses	168.50	165.29	73.51	333.79	170.02
<b>Total expenses</b>	<b>2,523.93</b>	<b>2,506.92</b>	<b>1,924.91</b>	<b>5,030.85</b>	<b>3,992.97</b>
<b>III Profit/(Loss) before exceptional items and tax</b>	<b>79.47</b>	<b>62.60</b>	<b>52.08</b>	<b>142.07</b>	<b>91.51</b>
<b>IV Exceptional items</b>					
<b>V Profit/(Loss) before tax</b>	<b>79.47</b>	<b>62.60</b>	<b>52.08</b>	<b>142.07</b>	<b>91.51</b>
<b>VI Tax expenses</b>					
a) Current tax	19.07	15.20	12.50	12.50	12.50
b) Deferred tax	-1.11	0.58	0.89	1.65	(1.65)
b) Mat Credit					
<b>VII Net Profit/(Loss) for the period/year</b>	<b>61.51</b>	<b>46.82</b>	<b>40.47</b>	<b>127.92</b>	<b>80.66</b>
<b>VIII Other comprehensive income (net of tax) loss:</b>	<b>54.14</b>				
				54.14	(162.77)
<b>Total other comprehensive income</b>	<b>54.14</b>			<b>54.14</b>	<b>(103.22)</b>
<b>Total comprehensive income for the period/year (VII+VIII)</b>	<b>115.65</b>	<b>46.82</b>	<b>40.47</b>	<b>182.06</b>	<b>(82.11)</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>			<b>1,752.27</b>	<b>3,444.87</b>	<b>1,752.27</b>
					<b>1,752.27</b>



XI	Other equity (excluding revaluation reserve)	5,167.57	5,104.74	2,332.55	5,167.57	2,332.55	2,518.51
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	0.04	0.03	0.23	0.04	0.46	0.25
	-Diluted	0.04	0.03	0.23	0.04	0.46	0.25

Notes:  
1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 12.11.2024 after being reviewed by the Audit Committee.

2. The company is having single segment in accordance with IND AS 108 "operating segments" and therefore segment reporting is not applicable to the Company.

3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajoora Biotech Limited  
  
 Jasjot Singh  
 Managing Director  
 DIN: 01937631

**JASJOT SINGH**  
 Digitally signed by JASJOT SINGH  
 Date: 2024.11.13 15:32:58 +05'30'

Place : Mohali  
 Date : 13.11.2024



# AJOONI BIOTECH LIMITED


Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
 Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
 E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
 CIN: L85190PB2010PLC040162

## CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2024

		Amount in Rs. (Lakhs)	
<b>"A" (1)</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Profit/(Loss) Before Tax		61.51
	Adjustments for:		
	Depreciation & Amortization	22.56	
	Interest & Finance Charges	5.90	
	Interest Income	-30.86	(2.40)
	<b>Operating Profit before Working Capital Changes</b>		59.11
	Adjustments for:		
	Decrease/(Increase) in Receivables	-1,037.49	
	Decrease/(Increase) in Inventories	-159.44	
	Decrease/(Increase) in Loans and Other Advances	-1,035.46	
	Decrease/(Increase) in Other Current Assets	-18.39	
	Increase/(Decrease) in Trade Payables	-158.45	
	Increase/(Decrease) in Other Current Liabilities	59.09	-2,350.13
	<b>Cash generated from operations</b>		(2,291.02)
	Tax paid prev year		(2,291.02)
	<b>Net Cash flow from Operating activities</b>		
<b>(2)</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Purchase of Tangible Assets/ Intangible Assets/ Capital Work-In-Progress		-64.47
	(Increase)/Decrease by sale/purchase in Non-Current Investment		-244.26
	Interest Income		30.86
	<b>Net Cash used in Investing activities</b>		-277.87
<b>(3)</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from/ (Repayment) of Long term Borrowings		51.39
	Proceeds from issue of share capital		1,692.60
	premium received		2,538.39



	Increase/(Decrease) in Short Term Borrowings	-48.57	
	Interest and Other Finance Costs paid	(5.90)	
	<b>Net Cash used in financing activities</b>		<b>4,227.90</b>
"B"	Net increase in cash & Cash Equivalents		<b>1,659.01</b>
	Add: Cash and Cash equivalents at the Beginning of the Year 1.04.2024		<b>42.82</b>
"c"	Cash & Cash Equivalents at 30.09.2024		<b>1,701.83</b>



Digitally signed  
 by JASJOT  
 SINGH  
 Date:  
 2024.11.13  
 15:33:04 +05'30'

JASJOT  
 SINGH

Statement of Assets and Liabilities  
 For the Year ended on 30th SEPTEMBER 2024


PARTICULARS	in Rs. (Lakhs)	
	30TH SEP 2024	31ST MARCH 2024
<b>I. ASSETS</b>		
<b>(1) Non - Current Assets</b>		
a) Property, Plant and Equipment	994.17	1,031.89
b) Capital Work In Progress	106.60	92.45
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets		-
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		-
(1) Investments	433.91	213.63
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets		-
i) Deffered Tax Asset (net)	32.33	31.22
j) Other Non Current Asset	200.00	150.00
<b>(2) Current Assets</b>		
a) Inventories	1,696.17	1,536.73
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,333.43	1,295.94
(3) Cash & Cash Equivalent	1,701.83	42.82
(4) Bank Balances other than (iii) above		
(5) Loans	1,386.88	351.42
(6) Other Financial Asset		0.00
c) Current Tax Assets (net)		-
d) Other Current Asset	24.32	5.93



TOTAL	8,909.64	4,752.04
<b><u>II EQUITY AND LIABILITIES</u></b>		
<b><u>(1) Equity</u></b>		
a) Equity Share Capital	3,444.87	1,752.27
b) Other Equity	5,167.57	2,518.51
<b><u>(2) Non-Current Liabilities</u></b>		
a) Financial Liabilities		
(1) Borrowings	219.59	168.20
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	13.04	11.99
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
<b><u>(3) Current Liabilities</u></b>		
a) Financial Liabilities		
(1) Borrowings	0.00	48.57
(2) Trade Payables	0.00	158.45
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	0.95	1.05
c) Other Current Liabilities	44.55	5.48
d) Current tax liabilities (Net)	19.07	87.50
<b>TOTAL</b>	8,909.64	4,752.04

Place : Mohali

Date : 13.11.2024



For Ajooni Biotech Limited

Jasjot Singh

\* Managing Director

DIN: 01937631

**JASJOT SINGH** Digitally signed  
by JASJOT SINGH  
Date: 2024.11.13  
15:33:16 +05'30'





**NARINDER KUMAR AND COMPANY**  
**CHARTERED ACCOUNTANTS**

SCO 65-B (1st Floor) City Heart,  
Kharar Chandigarh Road,  
Kharar, SAS Nagar Mohali-140301  
Mobile : 98154 50065  
Email : nkgargca@yahoo.co.in

Ref. No. ....

## Limited Review Report

Dated ..... 13.11.2024

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th September, 2024.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY  
Chartered Accountants



*Narinder Kumar Garg*  
(NARINDER KUMAR GARG)

PARTNER  
M.NO-080287

Date:-13.11.2024

UDIN:- 24080287BKBLOC9555